4th Quarter - Report

SPLITOAK STRATEGIES LLC for ALKERMES, INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings; H.R. 4030, Treatment Continuity Act of 2025

LobbyistCovered position, as disclosed
SARAH KUEHL EGGE Sarah: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 4030 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.